BioNTech’s Bold Gamble: Steering Through Financial Headwinds Towards a Cancer Revolution
BioNTech is shifting its focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies, with goals for market approval by 2026. In 2023, profits declined significantly, with revenue projections for 2024…